Managing Intellectual Property Magazine’s September 2014 cover story on the Patent Trial and Appeal Board (PTAB) discusses how the U.S. patent landscape has evolved since the signing of the America Invents Act (AIA) and the creation of the PTAB. The article recognized Finnegan as one of the top firms for petitioners filing for inter partes review (IPR) and covered business method (CBM) review.
The story is broken out into three sections. The first part takes an overall look at the rise of the PTAB, the surprise of patent owners at the increasing number of IPR and CBM petitions being filed, and what this could all mean for the Federal Circuit. Part two discusses how IPRs and the PTAB have specifically impacted the pharmaceutical industry. Finnegan partner Thomas L. Irving is quoted in the article, citing the pharmaceutical patent industry’s shock by the unexpected popularity of PTAB proceedings among generic pharmaceutical companies looking to invalidate the patents of larger pharmaceutical companies. Irving also shares advice for brand drug patent holders who are faced with protecting their patents in post-grant proceedings. Part three explores the challenges faced by both patent owners and lawyers as they navigate PTAB proceedings. These challenges primarily include the tight timeline, limited testimony and discovery, and the fact that patent owners are finding it difficult to amend claims. Finnegan attorneys Erika H. Arner and Joshua L. Goldberg provide insight into how lawyers can better equip themselves to adjust to these changes and prepare for appeals before the Board.
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Announcement
September 3, 2024
Announcement
Two Finnegan Partners Honored with Women, Influence, and Power in Law Awards
July 31, 2024
Media Mention
“This Was a Lie”: A Long but Partial List of “Flaws” Justifies Fees Shift
July 21, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.